Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.55 USD | -7.52% | -4.21% | +49.25% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 77.22M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -27M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.26
x | P/E ratio 2025 * |
-2.51
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.49% |
Latest transcript on Aileron Therapeutics, Inc.
1 day | -7.52% | ||
1 week | -4.21% | ||
1 month | -31.37% | ||
3 months | +2.94% | ||
6 months | +288.89% | ||
Current year | +49.25% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Director of Finance/CFO | 48 | 23-09-30 | |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 07-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-06-18 | |
Alan Musso
BRD | Director/Board Member | 61 | 23-10-30 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 4.55 | -7.52% | 319,110 |
24-04-29 | 4.92 | -1.60% | 159,753 |
24-04-26 | 5 | -.--% | 85,369 |
24-04-25 | 5 | +1.42% | 80,550 |
24-04-24 | 4.93 | +3.79% | 102,254 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.25% | 77.22M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.21% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- ALRN Stock